In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More contributors is going to be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "incorporate-on" therapy. In Section https://brd4-targeted-therapy-abb69024.blogdun.com/32536419/what-does-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-mean